Clinigen Group plc is a medical distribution business based in the UK. Clinigen Group shares (CLIN.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 629p – an increase of 1.04% over the previous week. Clinigen Group employs 1,150 staff and has a trailing 12-month revenue of around £504.3 million.
Since the stock market crash in March caused by coronavirus, Clinigen Group's share price has had significant negative movement.
Its last market close was 629p, which is 28.11% down on its pre-crash value of 875p and 79.51% up on the lowest point reached during the March crash when the shares fell as low as 350.4p.
If you had bought £1,000 worth of Clinigen Group shares at the start of February 2020, those shares would have been worth £416.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £660.01.
|Latest market close||629p|
|52-week range||347.2992p - 986.0158p|
|50-day moving average||652.6177p|
|200-day moving average||688.1303p|
|Wall St. target price||1259.67p|
|Dividend yield||0.08p (1.12%)|
|Earnings per share (TTM)||10.2p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||-2.11%|
|1 month (2020-12-22)||5.06%|
|3 months (2020-10-22)||21.93%|
|6 months (2020-07-22)||-7.58%|
|1 year (2020-01-22)||-29.58%|
|2 years (2019-01-22)||-9.27%|
|3 years (2018-01-22)||-36.70%|
|5 years (2016-01-22)||14.78%|
Valuing Clinigen Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinigen Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clinigen Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Clinigen Group shares trade at around 66x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Clinigen Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £122.6 million.
The EBITDA is a measure of a Clinigen Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£504.3 million|
|Operating margin TTM||14.65%|
|Gross profit TTM||£220 million|
|Return on assets TTM||4.18%|
|Return on equity TTM||3.1%|
|Market capitalisation||£901.9 million|
TTM: trailing 12 months
Dividend payout ratio: 67.65% of net profits
Recently Clinigen Group has paid out, on average, around 67.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinigen Group shareholders could enjoy a 1.12% return on their shares, in the form of dividend payments. In Clinigen Group's case, that would currently equate to about 0.08p per share.
Clinigen Group's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 5 November 2020 (the "ex-dividend date").
Over the last 12 months, Clinigen Group's shares have ranged in value from as little as 347.2992p up to 986.0158p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Clinigen Group's is 1.1344. This would suggest that Clinigen Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.